By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Aiming checkpoint regulators at immune diseases
AltruBio is a private company developing checkpoint-regulator monoclonal antibodies (mAbs) for treating immune disorders. The company uses its checkpoint regulators in a way it believes down-modulates overactivated T cells to restore natural homeostasis in treating autoimmune inflammation of T-cell-associated diseases, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes, and graft-versus-host disease (GVHD). Most of AltruBio’s development efforts are with neihulizumab (AbGn-168H), a potentially versatile molecule the company has dubbed “a pipeline in a product.” Neihulizumab is in Phase 1b trials for steroid refractory acute GVHD and frontline acute GVHD. A second compound, leiolizumab (AbGn-268), is in preclinical research.